BLA 761261 · Genzyme Corp
Xenpozyme
Olipudase Alfa-Rpcp · Injection
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Aug 31, 2022: To treat Acid Sphingomyelinase Deficiency
Last checked: Nov 20, 2026Latest source record: Dec 20, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Aug 31, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 1 recruiting
FAERS reports
137
32 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with XENPOZYME have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available during XENPOZYME administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue XENPOZYME immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reactions, a desensitization procedure to XENPOZYME may be considered [see Warnings and Precautions (5.1) ] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS See full prescribing information for complete boxed warning. Appropriate medical monitoring and support measures, including cardiopulmonary resuscitation equipment, should be readily available. If a severe...
What it is approved for
From the label in effect Dec 11, 2025.
XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. XENPOZYME is a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. ( 1 )
Mechanism: ASMD is a lysosomal storage disease that results from reduced activity of the enzyme acid sphingomyelinase (ASM), caused by pathogenic variants in the sphingomyelin phosphodiesterase 1 gene. ASM degrades sphingomyelin to ceramide and phosphocholine. The deficiency of ASM causes an intra-lysosomal accumulation of sphingomyelin (as well as cholesterol and other cell membrane lipids) in various tissues. XENPOZYME provides an exogenous source of ASM. XENPOZYME is not expected to cross the blood-brain barrier or modulate the CNS manifestations of ASMD.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 31, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
1 products under this application
- XENPOZYME · OLIPUDASE ALFA-RPCP 20MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olipudase Alfa" as an intervention, any sponsor and status, largest first.
- Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase DeficiencyPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02004691 · 36 participants · Start Dec 18, 2015 · Primary completion Mar 15, 2021
Drug: placebo (saline); Olipudase alfa · For: Sphingomyelin Lipidosis
Sites: San Francisco, California; Decatur, Georgia; The Bronx, New York · 24 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02004704 · 25 participants · Start Dec 4, 2013 · Primary completion Sep 6, 2023
Drug: GZ402665 · For: Sphingomyelin Lipidosis
Sites: New York, New York; Leuven, Belgium; Porto Alegre, Brazil · 9 sites in all
Genzyme, a Sanofi CompanySanofi (SNY)
NCT02292654 · 20 participants · Start May 1, 2015 · Primary completion Dec 9, 2019
Drug: Olipudase alfa · For: Sphingomyelin Lipidosis
Sites: New York, New York; Porto Alegre, Brazil; Bron, France · 6 sites in all
SanofiSanofi (SNY)
NCT06949358 · 3 participants · Start Nov 18, 2021 · Primary completion Apr 8, 2025
Drug: Olipudase alfa · For: Acid Sphingomyelinase Deficiency
Sites: Bron, France; Paris, France
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache10
- incorrect dose administered10
- weight increased10
- fatigue9
- nausea7
- off label use6
- vomiting6
- aspartate aminotransferase increased5
- condition aggravated5
- erythema5
- illness5
- pyrexia5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 39 |
| 2024 | 35 |
| 2025 | 29 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Current · updated Nov 19, 2026
Xenpozyme, Injection, 20 mg/5.1 mL (NDC 58468-0050-1). Supply concerns for late November through early December 2026; See the following site for additional information from Sanofi:...
Current · updated Nov 19, 2026
Xenpozyme, Injection, 4 mg/1.1 mL (NDC 58468-0051-1). Supply concerns for late November through early December 2026; See the following site for additional information from Sanofi:...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xenpozyme (Olipudase Alfa-Rpcp)
2024 spending
$6.6M
Beneficiaries
n/a
50 claims
Per beneficiary
n/a
$6,080.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $5,083,777 |
| 2024 | $6,644,633 |
Part B: Xenpozyme (Olipudase Alfa-Rpcp) · HCPCS J0218
2024 spending
$1.3M
Beneficiaries
n/a
18 claims
Per beneficiary
n/a
2024 ASP limit $379.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $1,345,196 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Long-Term Safety and Clinical Outcomes With Olipudase Alfa Enzyme Replacement Therapy in Children and Adolescents With Acid Sphingomyelinase Deficiency.
Scarpa M, Diaz GA, Giugliani R, et al. · J Inherit Metab Dis 2025 · Clinical Trial, Phase II, Multicenter Study
- A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results.
Wasserstein M, Lachmann R, Hollak C, et al. · Genet Med 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Adults With Acid Sphingomyelinase Deficiency Have Sustained Improvements in Clinical Outcomes With up to 5ߙYears of Olipudase Alfa Enzyme Replacement Therapy: ASCEND Trial Final Results.
Wasserstein MP, Hollak CE, Barbato A, et al. · J Inherit Metab Dis 2026 · Randomized Controlled Trial
- Efficacy and Safety of Olipudase Alfa for the Treatment of Acid Sphingomyelinase Deficiency (ASMD): A Systematic Review and Meta-Analysis.
Antonello BB, Giovacchini G, Albuquerque ALB, et al. · Am J Med Genet A 2026 · Systematic Review, Meta-Analysis
- Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment.
Thurberg BL, Diaz GA, Lachmann RH, et al. · Mol Genet Metab 2020 · Clinical Trial, Multicenter Study
- Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
Wasserstein MP, Diaz GA, Lachmann RH, et al. · J Inherit Metab Dis 2018 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.